The following is a summary of “Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic Designation,” published in the December ...
Among patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), valemetostat appears to induce durable responses, according to research published in The Lancet Oncology.